Prab: CSV import

2024-03-06T06:56:19Z

CSV import

New page

[[File:Tolimidone.svg|thumb|{{PAGENAME}}]]<br>'''Tolimidone''' is a [[pharmaceutical drug]] that was developed for the treatment of [[diabetes mellitus type 2]]. It belongs to the class of drugs known as [[hypoglycemic agents]], which are used to lower blood glucose levels in patients with diabetes. Tolimidone works by stimulating the release of [[insulin]] from the [[pancreas]], thereby reducing blood glucose levels.

== History ==

Tolimidone was first synthesized in the 1970s by the pharmaceutical company [[Lilly (company)|Eli Lilly and Company]]. It was marketed under the brand name [[Orinase]], but was later withdrawn from the market due to concerns about its safety profile.

== Pharmacology ==

Tolimidone is a [[sulfonylurea]], a class of drugs that stimulate the release of insulin from the pancreas. It works by binding to the [[sulfonylurea receptor]] on the pancreatic beta cells, which leads to an influx of calcium ions. This triggers the release of insulin, which in turn lowers blood glucose levels.

== Side Effects ==

Like other sulfonylureas, Tolimidone can cause [[hypoglycemia]] (low blood sugar) if taken in excess or if the patient does not eat enough. Other side effects can include [[nausea]], [[vomiting]], [[diarrhea]], and [[skin rash]]. In rare cases, Tolimidone can cause [[liver damage]].

== Withdrawal from Market ==

Tolimidone was withdrawn from the market due to concerns about its safety profile. Studies showed that it had a higher risk of causing liver damage compared to other sulfonylureas. As a result, it is no longer available for use.

== See Also ==

* [[Sulfonylurea]]
* [[Diabetes mellitus type 2]]
* [[Insulin]]
* [[Hypoglycemia]]

[[Category:Pharmaceutical drugs]]
[[Category:Diabetes]]
[[Category:Hypoglycemic agents]]
{{pharmacology-stub}}

Tolimidone - Revision history

Prab: CSV import